HERAN Partners invests in category leader for medical image analysis: Thirona

Oct 28, 2021 | Katleen Vandersmissen

Thirona (Nijmegen, NL), one of the leading companies specialised in artificial intelligence (AI) for medical image analysis, has closed its financing round with Belgian investment fund HERAN Partners and Borski Fund from the Netherlands. The proceeds of the financing round will be allocated to accelerate the Company’s transition towards market leadership in medical imaging.

Artificial intelligence (AI) solutions for lung and retinal image analysis

Thirona, founded in 2014 by female scientist Eva van Rikxoort, has rapidly transformed from a start-up to a category leader in the field of AI-powered medical image analysis. With its diverse team of sixty employees driven by an inclusive innovation culture, the Company develops highly innovative artificial intelligence solutions for both lung and retinal image analysis. Apart from focusing on the most common diseases such as Asthma, COPD, Age-related Macular Degeneration and Diabetic Retinopathy, Thirona is also tackling rare and complex conditions, such as Cystic Fibrosis and Idiopathic Pulmonary Fibrosis.

“We believe that science should be used for the benefit of all people. Our vision is to speed up scientific progress in healthcare by bringing together the best of science and technology. This to enable breakthroughs in treatment development and clinical care” - Eva van Rikxoort, founder and CEO of Thirona

Thirona focuses on translating AI-based technology into value-adding solutions and services in the entire spectrum of the clinical user – from clinical trials to clinics – through partnerships and integrations. With its flagship product, LungQ™, Thirona has built a proven track record as an expert partner for pharmaceutical companies, helping to advance treatment development in clinical trials, as well as supporting pulmonary clinical care across the globe.

HERAN Partners is committed to supporting Thirona's growth plans

Now that it is closing in on 10 million images analysed and its solutions have been validated in over 180 scientific publications, Thirona is looking to expand its operations and scale up its development efforts. Guido Geerts (co-CEO of Thirona) comments: “As a company, we have always placed a high emphasis on research and development which has enabled us to establish strong academic, clinical and industrial partnerships. Now, we find ourselves at a tipping point in our journey, expediting our international expansion and development goals. We are pleased to have found the right partners in HERAN Partners and Borski Fund to help accelerate our growth trajectory.”

“By tapping into the large market of non-oncologic lung diseases and through unparalleled innovation and high scalability of the platform, Thirona is poised to further strengthen its position as category leader in the market of image analysis. We at HERAN Partners are committed to supporting Thirona’s growth plans and provide them with capital, network, and expertise in global commercialisation” - Katleen Vandersmissen, Managing Partner at HERAN Partners.

“The combination of profound in house medical knowledge and deep learning expertise provides a unique technology platform in the field of medical image analysis. The robust scientific approach and focus on genuinely value adding propositions underpins the leadership of Eva and Guido, positioning Thirona to accelerate growth in a fast-expanding market. We are pleased to add Thirona to our portfolio as the third medical company. We look very much forward to supporting Eva and the management team in their personal and organisational growth”, Bertrand van Leersum, Investment Director at Borski Fund.

About Thirona

Thirona is an innovative Dutch Company specialised in artificial intelligence for medical image analysis. By providing highly reliable and user-friendly products and services, it bridges the gap between academic ideas and clinical use. Thirona partners with medical companies in their innovation trajectories and supports medical professionals in their daily tasks working with thoracic CT-scans (LungQ),chest X-rays (CAD4TB) and retinal scans (RetCAD). Since inception in 2014, Thirona has become an important player in the medical field with innovative AI-solutions used in over forty countries worldwide. For more information visit www.thirona.eu.

 

About Borski Fund

Borski Fund is a Dutch based venture capital fund investing in tech companies with a diverse management team. Founded by Simone Brummelhuis and Laura Rooseboom, Borski Fund strongly believes in diversity and gender equality. By investing in the growing group of female tech entrepreneurs the 50 million fund reduces the gender gap. Investments are made within the areas of Future of Health, Sustainable Transformation of Industries and Fashion Tech. The geographical focus is on Western Europe based companies with international ambitions. Borski Funds helps entrepreneurs realize their ambitions by leveraging own entrepreneurial experience and opening an extensive network. Borski Fund’s portfolio includes MedTech companies as Vivolta, leading the electro spun regenerative tissue engineering market and the Female Health company MyInnovo providing medical products to train the pelvic floor. For more information visit www.borskifund.com.

 

Join a Heran Fund

We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pitch your company

Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.